# References

Warrick, Joshua I., et al. "International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer—Principles of Classification and Emerging Clinical Utility." *The American journal of surgical pathology* 48.1 (2024): e32-e42.

Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." *European urology* 81.1 (2022): 75-94.

Aveta, Achille, et al. "The impact of meat intake on bladder cancer incidence: is it really a relevant risk?." *Cancers* 14.19 (2022): 4775.

Ibrahim, Nurul Khalida, et al. "Detection of cancer mutations by urine liquid biopsy as a potential tool in the clinical management of bladder cancer patients." *Cancers* 14.4 (2022): 969.

Gravas, Stavros, et al. "Summary paper on the 2023 European Association of Urology guidelines on the management of non-neurogenic male lower urinary tract symptoms." *European urology* 84.2 (2023): 207-222.

Mohanty, Sambit K., et al. "Precision medicine in bladder cancer: present challenges and future directions." *Journal of Personalized Medicine* 13.5 (2023): 756.

Zhang, Yongzhen, et al. "Identification of core genes and key pathways via integrated analysis of gene expression and DNA methylation profiles in bladder cancer." *Medical science monitor: international medical journal of experimental and clinical research* 24 (2018): 3024.

Bazargan, Sarah, et al. "Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer." *Frontiers in Immunology* 14 (2023): 1275375.

Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." *European urology* 81.1 (2022): 75-94.

Claps, Francesco, et al. "BCG-unresponsive non-muscle-invasive bladder cancer: current treatment landscape and novel emerging molecular targets." *International journal of molecular sciences* 24.16 (2023): 12596.

Tomko, Andrea M., Erin G. Whynot, and Denis J. Dupré. "Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer." *Journal of Cannabis Research* 4.1 (2022): 41.

Li, Changjiu, et al. "The oncogenic functions of SPARCL1 in bladder cancer." *Journal of Cellular and Molecular Medicine* 28.22 (2024): e70196.

Chen, Wujun, et al. "ALT-803 in the treatment of non-muscle-invasive bladder cancer: Preclinical and clinical evidence and translational potential." *Frontiers in Immunology* 13 (2022): 1040669.

Chen, Ji-Qing, et al. "Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes." *Clinical Epigenetics* 14.1 (2022): 14.

ŞEN, Selda, et al. "The effect of spinal and general anesthesia on metastatic lymph node flow in bladder cancer surgery: A pilot study." *Agri: Journal of the Turkish Society of Algology/Tu? rk Algoloji (Ag? r?) Derneg? i'nin Yayin Organidir* 33.3 (2021).

Ferlay, Jacques, et al.[[1]](#endnote-0) "Cancer statistics for the year 2020: An overview." *International journal of cancer* 149.4 (2021): 778-789.

1. Aveta, Achille, et al. "The impact of meat intake on bladder cancer incidence: is it really a relevant risk?." *Cancers* 14.19 (2022): 4775.

   Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." *European urology* 81.1 (2022): 75-94.

   Tran, Linda, et al. "Advances in bladder cancer biology and therapy." *Nature Reviews Cancer* 21.2 (2021): 104-121.

   Ferro, Matteo, et al. "Impact of age on outcomes of patients with pure carcinoma in situ of the bladder: multi-institutional cohort analysis." *Clinical Genitourinary Cancer* 20.2 (2022): e166-e172.

   Jubber, Ibrahim, et al. "Epidemiology of bladder cancer in 2023: a systematic review of risk factors." *European urology* 84.2 (2023): 176-190.

   Zhao, Xiaohu, Yuanli Wang, and Chaozhao Liang. "Cigarette smoking and risk of bladder cancer: a dose–response meta-analysis." *International urology and nephrology* 54.6 (2022): 1169-1185.

   Huan, Jianya, et al. "Emerging roles for mammalian target of rapamycin (mTOR) complexes in bladder cancer progression and therapy." *Cancers* 14.6 (2022): 1555.

   Goswami, Ritabrita, et al. "Nuclear localization signal-tagged systems: Relevant nuclear import principles in the context of current therapeutic design." *Chemical Society Reviews* (2024).

   Zuo, Mingshun, et al. "Sulforaphane and bladder cancer: a potential novel antitumor compound." *Frontiers in Pharmacology* 14 (2023): 1254236.

   Babjuk, Marko, et al. "European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)." *European urology* 81.1 (2022): 75-94.

   Jubber, Ibrahim, et al. "Epidemiology of bladder cancer in 2023: a systematic review of risk factors." *European urology* 84.2 (2023): 176-190.

   Adrien, Oriane, et al. "Prescribing cascades with recommendations to prevent or reverse them: a systematic review." *Drugs & Aging* 40.12 (2023): 1085-1100.

   Messina, Emanuele, et al. "Seeing is believing: state of the art imaging of bladder cancer." *Seminars in Radiation Oncology*. Vol. 33. No. 1. WB Saunders, 2023.

   Hu, Xinzi, Guangzhi Li, and Song Wu. "Advances in diagnosis and therapy for bladder cancer." *Cancers* 14.13 (2022): 3181.

   Bourlotos, Georgia, et al. "BCG induced lower urinary tract symptoms during treatment for NMIBC—Mechanisms and management strategies." *Frontiers in Neuroscience* 17 (2024): 1327053. [↑](#endnote-ref-0)